Immatics (IMTX) Non-Current Assets (2019 - 2025)
Immatics' (IMTX) quarterly Non-Current Assets came in at $67.9 million in Q4 2025, down 4.58% year-on-year from $71.2 million in Q4 2024, and down 4.06% quarter-over-quarter from $70.8 million in Q3 2025.
Immatics (IMTX) Non-Current Assets (2019 - 2025) Analysis & Trends
Immatics has disclosed Non-Current Assets across 7 years of filings, most recently posting $67.9 million for Q4 2025.
- Non-Current Assets for Q4 2025 came in at $67.9 million, down 4.58% year-over-year; the trailing twelve-month figure through Dec 2025 was $67.9 million (down 4.58% YoY), and the FY2025 annual result was $65.9 million, down 7.39% from the prior year.
- Non-Current Assets came in at $67.9 million for Q4 2025 at Immatics, down from $70.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $73.1 million in Q2 2024 to a low of $19.0 million in Q1 2021.
- The 5-year median for Non-Current Assets is $53.4 million (2023), against an average of $49.3 million.
- Across the five-year window, Non-Current Assets jumped 108.38% in 2023 and slipped 4.58% in 2025, its largest moves.
- Immatics' Non-Current Assets stood at $25.7 million in 2021, then advanced by 21.88% to $31.3 million in 2022, then surged by 108.38% to $65.2 million in 2023, then climbed by 9.15% to $71.2 million in 2024, then decreased by 4.58% to $67.9 million in 2025.
- The last three Non-Current Assets figures came in at $67.9 million (Q4 2025), $70.8 million (Q3 2025), and $71.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 67.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 67.90 Mn |
| Sep 30, 2025 | 70.77 Mn |
| Jun 30, 2025 | 71.73 Mn |
| Mar 31, 2025 | 71.66 Mn |
| Dec 31, 2024 | 71.16 Mn |
| Sep 30, 2024 | 70.79 Mn |
| Jun 30, 2024 | 73.07 Mn |
| Mar 31, 2024 | 70.32 Mn |
| Dec 31, 2023 | 65.20 Mn |
| Sep 30, 2023 | 57.09 Mn |
| Jun 30, 2023 | 49.62 Mn |
| Mar 31, 2023 | 35.89 Mn |
| Dec 31, 2022 | 31.29 Mn |
| Sep 30, 2022 | 32.25 Mn |
| Jun 30, 2022 | 34.44 Mn |
| Mar 31, 2022 | 24.99 Mn |
| Dec 31, 2021 | 25.67 Mn |
| Sep 30, 2021 | 22.14 Mn |
| Jun 30, 2021 | 21.88 Mn |
| Mar 31, 2021 | 19.03 Mn |